Protagonist Therapeutics (PTGX) stock forecast for 2022. Forecast tables and graphs.

Protagonist Therapeutics (PTGX) stock forecast for 2022

Last update: May 29, 2023 (05:11)

Sector: Healthcare

The share price of Protagonist Therapeutics, Inc. (PTGX) now

What analysts predict: $36.4
52-week High/Low: $26.87 / $6.91

50/200 Day Moving Average: $22.95 / $14.03

This figure corresponds to the Average Price over the previous 50/200 days. For Protagonist Therapeutics stocks, the 50-day moving average is the resistance level today.

For Protagonist Therapeutics stocks, the 200-day moving average is the resistance level today.

Are you interested in Protagonist Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Protagonist Therapeutics stock price in 2022. How much will one Protagonist Therapeutics share be worth in 2022? Is it worth taking profit / loss on Protagonist Therapeutics stock now or waiting? What are analysts' forecasts for Protagonist Therapeutics stock?

We forecast Protagonist Therapeutics stock performance using neural networks based on historical data on Protagonist Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Protagonist Therapeutics stock prediction results are shown below and presented as a graph, table and text information.

Protagonist Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Protagonist Therapeutics analysts is $36.4.

Today 200 Day Moving Average is the support level (14.03 $).

50 Day Moving Average is the support level (22.95 $).

Historical and forecast chart of Protagonist Therapeutics stock

The chart below shows the historical price of Protagonist Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Protagonist Therapeutics stock price can be found in the table below.

Protagonist Therapeutics (PTGX) Forecast for 2022

Month Target Pes. Opt. Vol., %

Protagonist Therapeutics information and performance

“Protagonist Therapeutics, Inc.” is a clinical stage biopharmaceutical company with a peptide technology platform focused on the discovery and development of new chemical entities (NECs) to meet significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. His main focus is on the development of oral peptide formulations that target biological pathways, also targeting commercially available injectable antibodies. PTG-100 is an oral peptide product of an alpha-4-beta-7 (a4b7) integrin antagonist candidate who has completed a phase I clinical trial in normal healthy volunteers (NHVs). PTH-100 is being developed for the treatment of moderate to severe ulcerative colitis (UC). PTG-200 is an oral interleukin-23 (IL-23R) receptor antagonist being developed for the treatment of moderate to severe Crohn’s disease. PTG-300 is an injectable hepcidin mimetic for the treatment of rare conditions associated with iron overload.

Protagonist Therapeutics Address


Market Capitalization: 1 502 847 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -145 250 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth


Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.


Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -2.94

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -1
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.84

Enterprise Value (EV) /Revenue

EV To EBITDA: -1.604

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 57251000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Protagonist Therapeutics price target for 2022 by month

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.